Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

St. John’s wort: expectations influence response

October 6, 2010

…e efficacy of St. John’s wort (Hypericum perforatum) extract and an active comparator (sertraline 50-100 mg/day) was not significantly different from placebo in the treatment of major depression (Hypericum Depression Trial Study Group. JAMA 2002; 287: 1807-1814; free full text athttp://jama.ama-assn.org/cgi/content/full/287/14/1807). A full response occurred in 23.9% of patients in the St. John’s wort group, 24.8% in the sertraline group, and 31.9…

Diagnosing pathological Internet use

October 6, 2010

…adian researchers see El-Guebaly & Mudry. World Psychiatry 2010; 9: 93-94; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2911084/?tool=pubmed). Clinical data are lacking, but a Problematic Internet Use Questionnaire is currently in development (Thatcher & Goolam. S Afr J Psychol 2005; 35: 793-809). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter…

Neuroleptic malignant syndrome: new diagnostic criteria proposed

September 29, 2010

…rrently defined as severe muscle rigidity and elevated temperature associated with the use of neuroleptic medication, and includes >2 of the following features: diaphoresis, dysphagia, tremor, incontinence, changes in level of consciousness ranging from confusion to coma, mutism, tachycardia, elevated/labile blood pressure, leucocytosis and laboratory evidence of muscle injury (APA. DSM-IV TR, Washington DC, 2000). Subscribe to read more It takes…

ECT: Response and common side effects

September 29, 2010

…Report from the 163rd annual meeting of the American Psychiatric Association, New Orleans LA, May 22-26, 2010 – Two studies have examined the effectiveness and side effect profile of electroconvulsive therapy (ECT) in patients with mood disorders. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Memantine in MS: no effect on cognitive performance

September 15, 2010

Memantine is an NMDA (N-methyl D-aspartate) receptor antagonist currently used in the treatment of Alzheimer’s disease. NMDA receptors appear to mediate oligodendrocyte injury and damage to the myelin sheath, and Canadian researchers have speculated that blocking these receptors may be clinically useful in MS (Stys & Lipson. Trends Pharmacol Sci 2007; 28: 561-566). Subscribe to read more It takes 30 seconds or login using your email address Pleas…